 |
|
|
| |
Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of MyrcludexB in combination with Tenofovirin patients with HBV/HDV coinfection
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
HeinerWedemeyer1, Pavel Bogomolov2, Antje Blank3,4, Lena Allweiss5,6, Maura Dandri-Petersen5,6, Birgit Bremer1, Natalia Voronkova2, KatrinSchöneweis4,7,11, Anita Pathil8, Jürgen Burhenne3,4, Mathias Haag9,10, Matthias Schwab9,10, Walter E. Haefeli3, Julian Schulze zurWiesch5,6, Alexander Alexandrov11,Stephan Urban4,7
1Hannover Medical School/Essen University Hospital, 2Moscow Regional Research Clinical Institute,3University Hospital Heidelberg, Dept. of Clinical Pharmacology, 4German Center for Infection Research (DZIF) Heidelberg, 5,University Medical Center Hamburg-Eppendorf,6DZIFLübeck-Borstel, 7University Hospital Heidelberg, Dept. of Infectious Diseases,8Internal Medicine IV, Heidelberg,9Dr. Margarete Fischer-Bosch-Institute, Stuttgart, 10DZIF Tübingen, 11MYR GmbH
|
| |
|
|
|
|
|
